AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18703544 — intervention group
Group type: COMPARATOR
Intervention: Waiting group (control)
Number of subjects: 61
Study 17219106 — intervention group
Group type: EXPERIMENTAL
Intervention: Full macular translocation (FMT)
Number of subjects: 50
Study 17219106 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 50
Study 15687942 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin + clavulanic acid 1g/125 mg administered from ovum pick-up day for 6 days
Number of subjects: 101
Study 15687942 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 101
Study 15687942 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin + clavulanic acid
Number of subjects: 101
Study 11570828 — intervention group
Group type: EXPERIMENTAL
Intervention: CDE reminder‐feedback plus educational outreach (Intervention Group)
Number of subjects: 318
Study 11570828 — intervention group
Group type: COMPARATOR
Intervention: Screening program (Control Group)
Number of subjects: 318
Study 9450157 — intervention group
Group type: EXPERIMENTAL
Intervention: pivagabine (900 mg/d)
Number of subjects: 100
Study 7949210 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg 4-hydroxyandrostenedione i.m. fortnightly
Number of subjects: 33
Study 7949210 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg 4-hydroxyandrostenedione i.m. fortnightly
Number of subjects: 33
Study 7949210 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 33
Study 3048754 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1 IV
Number of subjects: 35
Study 3048754 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 5 mg.kg‐1 IV
Number of subjects: 35
Study 3048754 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 35
Study 3048754 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 35
Study 29563043 — intervention group
Group type: EXPERIMENTAL
Intervention: Community gardening
Number of subjects: 312
Study 29563043 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 312
Study 28453754 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily mesalazine
Number of subjects: 83
Study 28453754 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily mesalazine
Number of subjects: 83
Study 26218845 — intervention group
Group type: EXPERIMENTAL
Intervention: B-GOS (galacto-oligosaccharide mixture)
Number of subjects: 40
Study 26218845 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 40
Study 23999693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab plus docetaxel
Number of subjects: 37
Study 23999693 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab plus docetaxel
Number of subjects: 37
Study 21055721 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis diagnosed by Nugent score ≥ 7 or vaginal pH ≥ 5
Number of subjects: 786
Study 21055721 — intervention group
Group type: COMPARATOR
Intervention: Control group (women not assigned to cerclage)
Number of subjects: 786
Study 18817348 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (oral hydrochloric acid sertraline, local inunction of traditional Chinese medicine, guidance in sexual psychology and knowledge)
Number of subjects: 110
Study 18817348 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral hydrochloric acid sertraline only)
Number of subjects: 110
Study 18817348 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 110
Study 18817348 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 17952073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankylosing spondylitis (AS)
Number of subjects: 1000
Study 17952073 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimmune thyroid disease (AITD)
Number of subjects: 1000
Study 17952073 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1000
Study 14975776 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise (n = 29)
Number of subjects: 54
Study 14975776 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity aerobic exercise (n = 25)
Number of subjects: 54
Study 11944739 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline, 5 mg, twice a day for 3 months
Number of subjects: 24
Study 11944739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9170771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management intervention
Number of subjects: 202
Study 9170771 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 202
Study 9170771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 202
Study 7964693 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (IDA)
Number of subjects: 2
Study 7964693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 3299442 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment (BT)
Number of subjects: 158
Study 3299442 — intervention group
Group type: COMPARATOR
Intervention: Blood Pressure Monitoring (BPM)
Number of subjects: 158
Study 3299442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (part of BT)
Number of subjects: 158
Study 29925383 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily
Number of subjects: 0
Study 29925383 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone (SFC) 50/500 μg twice daily
Number of subjects: 0
Study 27005294 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate plus propofol
Number of subjects: 400
Study 27005294 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 400
Study 24767476 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers with a tailored behavioral communication strategy and smartphone technology
Number of subjects: 0
Study 24767476 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers with an additional tailored behavioral communication strategy
Number of subjects: 0
Study 24767476 — intervention group
Group type: COMPARATOR
Intervention: Usual care (community health workers with the standard level of hypertension care training)
Number of subjects: 0
Study 22077914 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure suction drainage of 50 mmHg
Number of subjects: 169
Study 22077914 — intervention group
Group type: COMPARATOR
Intervention: High-pressure suction drainage of 700 mmHg
Number of subjects: 169
Study 20973966 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (300 mg/day for 25 weeks)
Number of subjects: 43
Study 20973966 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 18824949 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour-educational session with a specially trained nurse
Number of subjects: 182
Study 18824949 — intervention group
Group type: COMPARATOR
Intervention: Educational pamphlet
Number of subjects: 182
Study 15619385 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 2082
Study 15619385 — intervention group
Group type: COMPARATOR
Intervention: Balloon Angioplasty
Number of subjects: 2082
Study 15619385 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2082
Study 15619385 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 2082
Study 12010234 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for penile fracture
Number of subjects: 170
Study 12010234 — intervention group
Group type: COMPARATOR
Intervention: Control group (200 men)
Number of subjects: 170
Study 10660868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng (n = 7), receiving 350 mg of ginseng daily for 6 weeks
Number of subjects: 15
Study 10660868 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8), receiving a placebo daily for 6 weeks
Number of subjects: 15
Study 7848024 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 122
Study 7848024 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg once daily
Number of subjects: 122
Study 7848024 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg twice daily
Number of subjects: 122
Study 7848024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 7848024 — intervention group
Group type: EXPERIMENTAL
Intervention: All losartan dosages
Number of subjects: 122
Study 7848024 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg twice daily vs Losartan 100 mg once daily
Number of subjects: 122
Study 7848024 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily vs Losartan 50 mg twice daily
Number of subjects: 122
Study 7848024 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of hydrochlorothiazide 12.5 mg/d
Number of subjects: 122
Study 7848024 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (all dosages)
Number of subjects: 122
Study 2332095 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasta
Number of subjects: 14
Study 2332095 — intervention group
Group type: COMPARATOR
Intervention: Couscous
Number of subjects: 14
Study 367153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.5 microgram/kg)
Number of subjects: 13
Study 367153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.0625, 0.125, 0.25, and 0.5 microgram/kg)
Number of subjects: 13
Study 367153 — intervention group
Group type: COMPARATOR
Intervention: Low-calcium meal (100 mg)
Number of subjects: 13
Study 367153 — intervention group
Group type: COMPARATOR
Intervention: High-calcium meal (400 mg)
Number of subjects: 13
Study 31795748 — intervention group
Group type: COMPARATOR
Intervention: Complex decongestive treatment (n=38)
Number of subjects: 76
Study 31795748 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex decongestive treatment + intermittent pneumatic compression (n=38)
Number of subjects: 76
Study 31134436 — intervention group
Group type: EXPERIMENTAL
Intervention: 660‐nm diode laser; energy density = 1 J/cm2
Number of subjects: 40
Study 31134436 — intervention group
Group type: EXPERIMENTAL
Intervention: 660‐nm diode laser; energy density = 3 J/cm2
Number of subjects: 40
Study 31134436 — intervention group
Group type: EXPERIMENTAL
Intervention: 810‐nm diode laser; energy density = 1 J/cm2
Number of subjects: 40
Study 31134436 — intervention group
Group type: EXPERIMENTAL
Intervention: 810‐nm diode laser; energy density = 3 J/cm2
Number of subjects: 40
Study 31134436 — intervention group
Group type: COMPARATOR
Intervention: No laser treatment
Number of subjects: 40
Study 28386033 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural romifidine (50μg/kg)
Number of subjects: 18
Study 28386033 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural detomidine (50μg/kg)
Number of subjects: 18
Study 28386033 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (control)
Number of subjects: 18
Study 25585599 — intervention group
Group type: EXPERIMENTAL
Intervention: Total n-3 PUFAs
Number of subjects: 556
Study 25585599 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 556
Study 25585599 — intervention group
Group type: COMPARATOR
Intervention: n-6 PUFAs
Number of subjects: 556
Study 23370739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole added to current medications
Number of subjects: 0
Study 23370739 — intervention group
Group type: COMPARATOR
Intervention: Switching from ergot dopamine agonist to pramipexole
Number of subjects: 0
Study 21081553 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE membrane
Number of subjects: 18
Study 21081553 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic PEG
Number of subjects: 18
Study 21081553 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PTFE membrane and synthetic PEG
Number of subjects: 18
Study 21081553 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 18
Study 19958986 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascugel
Number of subjects: 65
Study 19958986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 17719306 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Exercise (WE)
Number of subjects: 34
Study 17719306 — intervention group
Group type: EXPERIMENTAL
Intervention: Land Exercise (LE)
Number of subjects: 34
Study 17719306 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 15042481 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroverine
Number of subjects: 20
Study 15042481 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine, Glutamate, Glutamic acid
Number of subjects: 20
Study 15042481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11601957 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality indicators for pneumonia management in vulnerable elders
Number of subjects: 0
Study 9722252 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 120
Study 9722252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8974379 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (calcium acetylhomotaurinate)
Number of subjects: 272
Study 8974379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 2926224 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional CT imaging
Number of subjects: 20
Study 2926224 — intervention group
Group type: COMPARATOR
Intervention: Plain radiographs and computed tomography
Number of subjects: 20
Study 785019 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid therapy
Number of subjects: 48
Study 785019 — intervention group
Group type: COMPARATOR
Intervention: No antacid therapy
Number of subjects: 48
Study 31246632 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 45
Study 31246632 — intervention group
Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 45
Study 31246632 — intervention group
Group type: COMPARATOR
Intervention: Enteral plus Total Parenteral Nutrition (EN+TPN)
Number of subjects: 45
Study 28745578 — intervention group
Group type: EXPERIMENTAL
Intervention: G5 Mobile continuous glucose monitoring (CGM)
Number of subjects: 0
Study 28745578 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 0
Study 28745578 — intervention group
Group type: EXPERIMENTAL
Intervention: G5 Mobile CGM vs SMBG
Number of subjects: 0
Study 26539982 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg∙kg‐1)
Number of subjects: 10
Study 23384736 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaphorical monitor
Number of subjects: 32
Study 23384736 — intervention group
Group type: COMPARATOR
Intervention: Standard monitor
Number of subjects: 32
Study 23384736 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaphorical monitor with trend arrows
Number of subjects: 32
Study 23384736 — intervention group
Group type: COMPARATOR
Intervention: Metaphorical monitor without trend arrows
Number of subjects: 32
Study 22140661 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless protocol
Number of subjects: 60
Study 22140661 — intervention group
Group type: COMPARATOR
Intervention: Flap protocol
Number of subjects: 60
Study 19041111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sewerage system connection (intervention group)
Number of subjects: 4179
Study 19041111 — intervention group
Group type: COMPARATOR
Intervention: No sewerage system connection (control group)
Number of subjects: 4179
Study 17874717 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) and physical therapy
Number of subjects: 42
Study 15294263 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 0
Study 15294263 — intervention group
Group type: COMPARATOR
Intervention: No ICD therapy
Number of subjects: 0
Study 11721321 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA 1 (omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg, twice daily for one week)
Number of subjects: 113
Study 11721321 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA 2 (omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg, twice daily for two weeks)
Number of subjects: 113
Study 11721321 — intervention group
Group type: EXPERIMENTAL
Intervention: OCM (omeprazole 20 mg, clarithromycin 500 mg, metronidazole 500 mg, twice daily for one week)
Number of subjects: 113
Study 9248896 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nitrogen therapy
Number of subjects: 468
Study 9248896 — intervention group
Group type: COMPARATOR
Intervention: Other known treatment modalities
Number of subjects: 468
Study 7524833 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 200/0.62
Number of subjects: 6
Study 7524833 — intervention group
Group type: COMPARATOR
Intervention: 6% HES 200/0.5
Number of subjects: 6
Study 2889555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (60 micrograms/kg bolus + 1 microgram/min/kg infusion) with halothane anesthesia
Number of subjects: 0
Study 2889555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (60 micrograms/kg bolus + 1 microgram/min/kg infusion) with fentanyl anesthesia
Number of subjects: 0
Study 30152527 — intervention group
Group type: COMPARATOR
Intervention: SENS-111 (100-500 mg single doses; 50-150 mg/day for 4 days; 200-250 mg/day for 7 days)
Number of subjects: 100
Study 30152527 — intervention group
Group type: EXPERIMENTAL
Intervention: SENS-111 (100-200 mg/day)
Number of subjects: 100
Study 23982695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized black raspberries (BRBs) 45 g/d for 4 days followed by HFHC breakfast with BRBs
Number of subjects: 10
Study 23982695 — intervention group
Group type: COMPARATOR
Intervention: HFHC breakfast without previous consumption of BRBs
Number of subjects: 10
Study 26306861 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 240
Study 26306861 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with early stage COPD
Number of subjects: 240
Study 26306861 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 240
Study 26306861 — intervention group
Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 240
Study 23867998 — intervention group
Group type: COMPARATOR
Intervention: Standard office hour appointment
Number of subjects: 9410
Study 23867998 — intervention group
Group type: EXPERIMENTAL
Intervention: Office hour appointment with the option to change to out-of-hours appointment
Number of subjects: 9410
Study 23867998 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekday evening appointment
Number of subjects: 9410
Study 23867998 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend appointment
Number of subjects: 9410
Study 20966375 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Shape Up RI program plus video lessons on weight loss (Study 1)
Number of subjects: 0
Study 20966375 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Shape Up RI program plus video lessons, daily self-monitoring of weight, eating, and exercise, and computer-generated feedback (Study 2)
Number of subjects: 0
Study 18940276 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 10548
Study 18940276 — intervention group
Group type: COMPARATOR
Intervention: No lipid-lowering therapy
Number of subjects: 10548
Study 15752106 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-freshening flavours in whole products
Number of subjects: 0
Study 15752106 — intervention group
Group type: COMPARATOR
Intervention: Products containing 0.1% (w/w) triclosan or 0.2% (w/w) zinc sulphate
Number of subjects: 0
Study 14624424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 1308
Study 14624424 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 1308
Study 14624424 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 1308
Study 15089787 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tropicamide
Number of subjects: 30
Study 15089787 — intervention group
Group type: COMPARATOR
Intervention: 1% tropicamide
Number of subjects: 30
Study 10544423 — intervention group
Group type: EXPERIMENTAL
Intervention: Grunting during deadlifts
Number of subjects: 31
Study 10544423 — intervention group
Group type: COMPARATOR
Intervention: No grunting during deadlifts
Number of subjects: 31
Study 7546754 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 59
Study 7546754 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 59
Study 2224134 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.0 Gy TBI
Number of subjects: 71
Study 2224134 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.75 Gy TBI
Number of subjects: 71
Study 705282 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (20 min/day of peroneal nerve stimulation)
Number of subjects: 49
Study 705282 — intervention group
Group type: COMPARATOR
Intervention: Traditional physiotherapy treatment (1 hour/day)
Number of subjects: 49
Study 31012119 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 80
Study 31012119 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 80
Study 28166849 — intervention group
Group type: EXPERIMENTAL
Intervention: MeMOS condition (continuous feedback on patient progress to both therapist and supervisor)
Number of subjects: 0
Study 28166849 — intervention group
Group type: COMPARATOR
Intervention: S-Sup condition (feedback only to the therapist)
Number of subjects: 0
Study 25959558 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose followed by 10 mg daily maintenance dose (n=19)
Number of subjects: 39
Study 25959558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose followed by 90 mg twice daily maintenance dose (n=20)
Number of subjects: 39
Study 23746674 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiation (CRT) to a dose of 66 Gy in 33 fractions over 6.5 weeks with concurrent cisplatin (100 mg/m(2) on days 1, 22 and 43)
Number of subjects: 216